Trading Report: The Abeona Therapeutics Inc. (ABEO) Given Buy Rating at Maxim Group

The Abeona Therapeutics Inc. (ABEO) Given Buy Rating at Maxim Group

Maxim Group reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Wednesday. The firm currently has a $14.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on ABEO. Zacks Investment Research cut Abeona Therapeutics from a hold rating to a sell rating in a report on Monday, July 4th. Cantor Fitzgerald reissued a buy rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, September 30th. FBR & Co set a $15.00 price target on Abeona Therapeutics and gave the stock a buy rating in a report on Thursday, August 18th. Finally, Rodman & Renshaw reissued a buy rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Sunday, August 21st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $14.50.

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.54 on Wednesday. Abeona Therapeutics has a one year low of $2.05 and a one year high of $7.19. The firm has a 50-day moving average price of $5.43 and a 200 day moving average price of $3.49. The stock’s market capitalization is $219.38 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. On average, equities analysts expect that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.

In other news, Director Todd Wider purchased 5,000 shares of the stock in a transaction on Tuesday, September 20th. The stock was purchased at an average price of $5.48 per share, with a total value of $27,400.00. Following the completion of the transaction, the director now owns 75,000 shares in the company, valued at $411,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 13.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Royce & Associates LP boosted its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC boosted its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares in the last quarter. Institutional investors own 19.95% of the company’s stock.

About Abeona Therapeutics

Related posts

Leave a Comment